Literature DB >> 27865148

Plasma adrenomedullin in critically ill patients with sepsis after major surgery: A pilot study.

Tim-Philipp Simon1, Lukas Martin1, Sabine Doemming1, Andreas Humbs1, Christian Bruells1, Ruedger Kopp1, Oliver Hartmann2, Joachim Struck2, Andreas Bergmann2, Gernot Marx1, Tobias Schuerholz3.   

Abstract

PURPOSE: Adrenomedullin is released by different tissues in hypoxia, oxidative stress, and inflammation and is found in general and medical patients and, recently, in sepsis patients in emergency departments. The aim of this study was to evaluate biologically active adrenomedullin that mirrors directly the active peptide levels in plasma of surgical intensive care unit (ICU) patients with sepsis.
MATERIALS AND METHODS: In this single-center observational pilot trial, 42 ICU patients with sepsis and 14 patients after major surgery were included after sepsis diagnosis or ICU admission.
RESULTS: Patients (66% male) were 70 (median) (interquartile range [IQR], 61-77]) years old and had a body mass index of 26.2 (24.2-29.4) kg/m2. The ICU and hospital length of stay was 8 (1-22) and 17 (8-21) days, respectively. Eight patients had sepsis, 19 developed severe sepsis, and 15 suffered from septic shock. Adrenomedullin increased with severity (sepsis: 25.8 pg/mL [IQR 20.3-40.2], severe sepsis: 84.2 pg/mL [IQR 42.7-118.5], septic shock: 119.7 pg/mL [IQR 83.8-172.6]; P<.0001). Higher adrenomedullin was associated with poor 90-day outcomes (P=.019) and more frequent vasopressor use (P=.001).
CONCLUSIONS: This is the first study investigating adrenomedullin in patients with sepsis following major surgery. Higher adrenomedullin on admission is associated with increased vasopressor need and mortality after 90 days. Thus, adrenomedullin may be a useful additional parameter in surgical patients with sepsis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adrenomedullin; Biomarker; Intensive care; Sepsis; Surgical

Mesh:

Substances:

Year:  2016        PMID: 27865148     DOI: 10.1016/j.jcrc.2016.10.017

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  7 in total

1.  Human adrenomedullin and its binding protein attenuate tissue injury and inflammation following hepatic ischemia reperfusion in rabbits.

Authors:  Asha Jacob; Zhimin Wang; Hao Ting Yen; Ping Wang
Journal:  Heliyon       Date:  2021-08-20

Review 2.  Adrenomedullin, a Novel Target for Neurodegenerative Diseases.

Authors:  Hilda Ferrero; Ignacio M Larrayoz; Francisco J Gil-Bea; Alfredo Martínez; María J Ramírez
Journal:  Mol Neurobiol       Date:  2018-03-29       Impact factor: 5.590

3.  Identification of key pathogenic genes of sepsis based on the Gene Expression Omnibus database.

Authors:  Xinxing Lu; Lu Xue; Wenbin Sun; Jilu Ye; Zhiyun Zhu; Haifeng Mei
Journal:  Mol Med Rep       Date:  2017-12-12       Impact factor: 2.952

4.  Adrenomedullin and Its Possible Role in Improved Survival in Female Patients with Sepsis: A Study in the South East Asian Region.

Authors:  Mradul K Daga; Lalit Kumar; Govind Mawari; Naresh Kumar; Shashank Singh; Tarun Kumar Mishra
Journal:  Indian J Crit Care Med       Date:  2020-12

5.  The usefulness of plasma levels of mature and total adrenomedullin as biomarkers indicating the magnitude of surgical stress responses: A single-center, prospective, observational study.

Authors:  Go Otao; Toyoaki Maruta; Tetsu Yonaha; Koji Igarashi; Sayaka Nagata; Kazuo Kitamura; Isao Tsuneyoshi
Journal:  J Clin Transl Res       Date:  2021-05-14

6.  [Sepsis in German intensive care units-Last position worldwide?… Not so fast].

Authors:  Michael Bauer; Heinrich Volker Groesdonk; Franziska Preissing; Petra Dickmann; Tobias Vogelmann; Herwig Gerlach
Journal:  Anaesthesist       Date:  2021-06-21       Impact factor: 1.041

7.  Bioactive adrenomedullin a prognostic biomarker in patients with mild to moderate dyspnea at the emergency department: an observational study.

Authors:  Kevin Bronton; Torgny Wessman; Klas Gränsbo; Janin Schulte; Oliver Hartmann; Olle Melander
Journal:  Intern Emerg Med       Date:  2021-06-26       Impact factor: 5.472

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.